Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Caitlin E. Cox

October 05, 2018

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

News Daily News

Drug-Coated Balloon Gets Expanded Indication for In-Stent Restenosis in PAD

Todd Neale

September 13, 2016

News Daily News

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

Caitlin E. Cox

July 07, 2016

News Daily News

MARIS登记处：镍钛合金支架对“真实”SFA患者安全、有效

October 03, 2014

News Daily News

MARIS Registry: Nitinol Stent Appears Safe, Effective in ‘Real World’ SFA Patients

October 03, 2014

News Daily News

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

May 30, 2014

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

News Daily News

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

Jason Kahn

February 20, 2014

News Daily News

Bioresorbable Scaffold Designed for PAD Yields Good Early Results

January 22, 2014

News Daily News

STROLL at 3 Years: Nitinol Stent Demonstrates Sustained Patency, QoL in SFA Patients

L.A. McKeown

January 20, 2014

News Daily News

Zilver Stent Seen as Welcome Addition to PAD Armamentarium

L.A. McKeown

November 25, 2012

News Daily News

Drug-Eluting Balloon Continues Strong Showing in SFA Lesions

Jason Kahn

March 22, 2012

News Daily News

Drug-Eluting Balloon Continues to Show Positive Results in SFA, Popliteal Disease

Jason Kahn

September 15, 2011

Advertisement

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

Drug-Coated Balloon Gets Expanded Indication for In-Stent Restenosis in PAD

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

MARIS登记处：镍钛合金支架对“真实”SFA患者安全、有效

MARIS Registry: Nitinol Stent Appears Safe, Effective in ‘Real World’ SFA Patients

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

Bioresorbable Scaffold Designed for PAD Yields Good Early Results

STROLL at 3 Years: Nitinol Stent Demonstrates Sustained Patency, QoL in SFA Patients

Zilver Stent Seen as Welcome Addition to PAD Armamentarium

Drug-Eluting Balloon Continues Strong Showing in SFA Lesions

Drug-Eluting Balloon Continues to Show Positive Results in SFA, Popliteal Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content